Bochie that jump in sales is mainly a function of screening sales taking off.
Realisticaly it will take GBI a few years to build up a reasonable set of data (marketing material) for screening sales to become meaningful...that number in 2012 assumes a PapType market share of 10% of screening tests and 50% of Australia & NZ markets.
In screening market 2010 market share assumed is 2% whilst 2011 is 4%.
The ASCUS/triage sales from 2010-2011 are the low hanging fruit so to speak and can get GBI profitable whilst building the data for the larger screening market.
cheers
GBI Price at posting:
50.0¢ Sentiment: Buy Disclosure: Held
